Table 1 Patient demographics and clinical characteristics
Characteristics | HypoTRT group (n = 69) | ConvTRT group (n = 101) | P |
|---|---|---|---|
Gender | 0.414 | ||
Male | 57(82.6%) | 88(87.1%) | |
Female | 12(17.4%) | 13(12.9%) | |
Age (yr) | 0.698 | ||
Median | 59 | 57 | |
Range | 31–76 | 38–83 | |
Smoking | 0.403 | ||
Yes | 48(69.6%) | 64(63.4%) | |
No | 21(30.4%) | 37(36.6%) | |
Performance status(ECOG) | 0.564 | ||
0–1 | 65(94.2%) | 92(91.1%) | |
2 | 4(5.8%) | 9(8.9%) | |
TNM stage | 0.761 | ||
I-II | 10(14.5%) | 13(12.9%) | |
III | 59(85.5%) | 88(87.1%) | |
CRT modality | <0.001 | ||
Concurrent CRT | 63(91.3%) | 50(49.5%) | |
Early radiotherapy | 53 | 34 | |
Late radiotherapy | 10 | 16 | |
Sequential CRT | 6(8.7%) | 51(50.5%) | |
Cycles of chemotherapy | 0.924 | ||
<4 cycles | 12(17.4%) | 17(16.8%) | |
≥4 cycles | 57(82.6%) | 84(83.2%) | |
PCI | 0.014 | ||
Yes | 46(66.7%) | 48(47.5%) | |
No | 23(33.3%) | 53(52.5%) |